Literature DB >> 23053158

Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma.

B Greve1, F Sheikh-Mounessi, B Kemper, I Ernst, M Götte, H T Eich.   

Abstract

BACKGROUND AND
PURPOSE: Radiotherapy constitutes an essential element in the multimodal therapy of Ewing's sarcoma. Compared to other sarcomas, Ewing tumors normally show a good response to radiotherapy. However, there are consistently tumors with a radioresistant phenotype, and the underlying mechanisms are not known in detail. Here we investigated the association between survivin protein expression and the radiosensitivity of Ewing's sarcoma in vitro.
MATERIAL AND METHODS: An siRNA-based knockdown approach was used to investigate the influence of survivin expression on cell proliferation, double-strand break (DSB) induction and repair, apoptosis and colony-forming ability in four Ewing's sarcoma cell lines with and without irradiation.
RESULTS: Survivin protein and mRNA were upregulated in all cell lines tested in a dose-dependent manner. As a result of survivin knockdown, STA-ET-1 cells showed reduced cell proliferation, an increased number of radiation-induced DSBs, and reduced repair. Apoptosis was increased by knockdown alone and increased further in combination with irradiation. Colony formation was significantly reduced by survivin knockdown in combination with irradiation.
CONCLUSION: Survivin is a radiation-inducible protein in Ewing's sarcoma and its down-regulation sensitizes cells toward irradiation. Survivin knockdown in combination with radiation inhibits cell proliferation, repair, and colony formation significantly and increases apoptosis more than each single treatment alone. This might open new perspectives in the radiation treatment of Ewing's sarcoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053158     DOI: 10.1007/s00066-012-0223-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  41 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Use of radiation therapy for patients with soft-tissue and bone sarcomas.

Authors:  Lawrence J Sheplan; Justin J Juliano
Journal:  Cleve Clin J Med       Date:  2010-03       Impact factor: 2.321

3.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.

Authors:  Takehiko Dohi; Fang Xia; Dario C Altieri
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

4.  Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.

Authors:  Daniella Pfeifer; Asa Wallin; Birgitta Holmlund; Xiao-Feng Sun
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-06       Impact factor: 4.553

5.  A rapid flow cytometric method for bivariate bromodeoxyuridine/DNA analysis using simultaneous proteolytic enzyme digestion and acid denaturation.

Authors:  P E van Erp; P P Brons; J B Boezeman; G J de Jongh; F W Bauer
Journal:  Cytometry       Date:  1988-11

6.  Isolation of synaptic terminals from Alzheimer's disease cortex.

Authors:  Sophie Sokolow; Kristen M Henkins; Iris A Williams; Harry V Vinters; Ingrid Schmid; Gregory M Cole; Karen H Gylys
Journal:  Cytometry A       Date:  2011-12-28       Impact factor: 4.355

Review 7.  Survivin in solid tumors: rationale for development of inhibitors.

Authors:  David N Church; Denis C Talbot
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 8.  Targeting survivin in cancer therapy.

Authors:  Marzia Pennati; Marco Folini; Nadia Zaffaroni
Journal:  Expert Opin Ther Targets       Date:  2008-04       Impact factor: 6.902

9.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.

Authors:  Giuseppe Giaccone; Petr Zatloukal; Jaromir Roubec; Karijn Floor; Jaromir Musil; Milan Kuta; Rob J van Klaveren; Subhash Chaudhary; Adrie Gunther; Setareh Shamsili
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 50.717

10.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes.

Authors:  Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583

View more
  16 in total

1.  Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.

Authors:  C Blattmann; M Thiemann; A Stenzinger; A Christmann; E Roth; V Ehemann; J Debus; A E Kulozik; W Weichert; P E Huber; S Oertel; A Abdollahi
Journal:  Strahlenther Onkol       Date:  2013-06-27       Impact factor: 3.621

2.  Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Martina Vetter; Peter Würl; Hans J Holzhausen; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

3.  Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.

Authors:  Sagar Shelake; Umesh T Sankpal; W Paul Bowman; Matthew Wise; Anish Ray; Riyaz Basha
Journal:  Invest New Drugs       Date:  2016-12-26       Impact factor: 3.850

4.  Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.

Authors:  E-M Thurner; S Krenn-Pilko; U Langsenlehner; W Renner; A Gerger; K S Kapp; T Langsenlehner
Journal:  Strahlenther Onkol       Date:  2014-01-16       Impact factor: 3.621

5.  Ewing's sarcoma of the larynx. Effective treatment with organ preservation.

Authors:  A Wygoda; T Rutkowski; D Ponikiewska; B Hejduk; K Składowski
Journal:  Strahlenther Onkol       Date:  2013-06-05       Impact factor: 3.621

Review 6.  DNA damage and the balance between survival and death in cancer biology.

Authors:  Wynand P Roos; Adam D Thomas; Bernd Kaina
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

7.  SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy.

Authors:  Jordan A Naumann; John C Widen; Leslie A Jonart; Maryam Ebadi; Jian Tang; David J Gordon; Daniel A Harki; Peter M Gordon
Journal:  Bioconjug Chem       Date:  2018-02-19       Impact factor: 4.774

8.  Identifying fates of cancer cells exposed to mitotic inhibitors by quantitative phase imaging.

Authors:  Dian Huang; Irena J Roy; Graeme F Murray; Jason Reed; Thomas A Zangle; Michael A Teitell
Journal:  Analyst       Date:  2019-12-16       Impact factor: 4.616

9.  Quantitative stain-free and continuous multimodal monitoring of wound healing in vitro with digital holographic microscopy.

Authors:  Dominik Bettenworth; Philipp Lenz; Philipp Krausewitz; Markus Brückner; Steffi Ketelhut; Dirk Domagk; Björn Kemper
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

10.  PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Authors:  Chiara Giorgi; Aleksandar Boro; Florian Rechfeld; Laura A Lopez-Garcia; Maria E Gierisch; Beat W Schäfer; Felix K Niggli
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.